ImpediMed

ImpediMed Book Value Growth

The Book Value Growth of ImpediMed (IPD.AX) as of Nov 12, 2026 is -50.30 %. In the previous year, Book Value Growth was -49.69 % — a change of 1.21% (lower).

Book Value Growth

-50.30 %

YoY

1.21%

Last updated:

Book Value Growth of ImpediMed is 2026 -50.30 % . Book Value Growth of ImpediMed was 2025 -49.69 % . It decreases by 1.21% lower compared to the previous year.

The ImpediMed Book Value Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value Growth
Date
Book Value Growth
Jan 1, 2019
-55.91 AUD
Jan 1, 2020
73.34 AUD
Jan 1, 2021
-6.75 AUD
Jan 1, 2022
100.06 AUD
Jan 1, 2023
19.27 AUD
Jan 1, 2024
-33.08 AUD
Jan 1, 2025
-49.69 AUD
Jan 1, 2026
-50.30 AUD
The ImpediMed Book Value Growth history
YEARBook Value GrowthYoY
-50.30 %+1.21%
-49.69 %+50.25%
-33.08 %-271.66%
19.27 %-80.74%
100.06 %-1,582.30%
-6.75 %-109.20%
73.34 %-231.16%
-55.91 %+42.98%
-39.11 %+26.01%
-31.03 %-121.44%
144.72 %-8.08%
157.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Book Value Growth of ImpediMed is -50.30 % in 2026.

On Eulerpool you can find the complete historical development of Book Value Growth ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Book value growth measures the percentage increase in shareholders' equity. It indicates how effectively the company retains and grows its net assets.

To evaluate Book Value Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Book Value Growth.

Book Value Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Book Value Growth's ImpediMed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — ImpediMed

All Key Metrics — ImpediMed